Search SGHT
Sight Sciences, Inc.
Nasdaq · CIK 1531177
Last close8.53
Daily change-0.50 (-5.54%)
10 Years gain-74.54%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
SGHT · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
48.4Momentum
100.0Acceleration
100.0Confidence
83.0Annual Revenue6
Quarterly Revenue23
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth4.8 / 25
Quality19.2 / 25
Capital Efficiency9.3 / 20
Balance Sheet9.3 / 15
Shareholder Economics3.3 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 1.7198 percentage points.
Operating leverageOperating margin improved by 20.1351 percentage points.
ROIC expansionROIC improved by 53.3251 percentage points.
Warnings
Low interest coverage · HIGHInterest coverage is -6.9683x.
Key Metrics
Revenue Growth TTM5.69%OK
Revenue CAGR 3Y2.74%OK
Gross Margin87.38%OK
Operating Margin-43.45%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-225.3%OK
Incremental Operating Margin 3Y596.76%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y6.27%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $77.36M | $66.67M | -$37.10M | -$29.69M | -$29.92M | 86.17% | -47.95% | -38.67% | -272.34% | 52.15M |
| 2025 FY Dec 31, 2024 | $79.87M | $68.29M | -$50.53M | -$22.35M | -$22.74M | 85.5% | -63.27% | -28.47% | -329.21% | 50.13M |
| 2024 FY Dec 31, 2023 | $81.06M | $69.18M | -$57.27M | -$47.18M | -$47.98M | 85.34% | -70.66% | -59.19% | -333.16% | 48.63M |
| 2023 FY Dec 31, 2022 | $71.33M | $58.97M | -$83.95M | -$75.97M | -$76.94M | 82.67% | -117.7% | -107.86% | -804.12% | 47.85M |
| 2022 FY Dec 31, 2021 | $48.96M | $40.35M | -$51.48M | -$52.54M | -$53.35M | 82.41% | -105.15% | -108.98% | n/a | 26.73M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $82.56M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-335204, 0001193125-25-269613 |
| Revenue Growth TTM | 5.69% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-335204, 0001193125-25-269613 |
| Revenue CAGR 3Y | 2.74% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-091558 |
| Revenue CAGR 5Y | 22.86% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-091558 |
| Gross Profit CAGR 3Y | 4.17% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-091558 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-335204, 0001193125-25-269613 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 87.38% | Gross Profit / Revenue | OK | 0001193125-26-335204, 0001193125-25-269613 |
| Operating Margin | -43.45% | Operating Income / Revenue | OK | 0001193125-26-335204, 0001193125-25-269613 |
| ROIC | -225.3% | NOPAT / Average Invested Capital | OK | 0001193125-26-335204, 0001193125-25-269613 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-335204 |
| Interest Coverage | -6.97x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 4.95x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.96x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-335204 |